Metabolism - Clinical and Experimental
Volume 44 , Pages 37-44 , October 1995

Free insulin-like growth factors in human obesity

References 

  1. Strobl JS, Thomas JT. Human growth hormone. Pharmacol Rev. 1994;46:1–34
  2. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15:80–101
  3. Ross RJM. Growth hormone secretion: Its regulation and the influence of nutritional factors. Nutr Res Rev. 1990;3:143–162
  4. Glass AR, Burman KD, Dahms WT, et al.  Endocrine function in human obesity. Metabolism. 1981;30:89–104
  5. Rudman D, Kutner MH, Rogers CM, et al.  Impaired growth hormone secretion in the adult population: Relation to age and adiposity. J Clin Invest. 1981;67:1361–1369
  6. Copeland KC, Colletti RB, Devlin JT, et al.  The relationship between insulin-like growth factor-I, adiposity, and aging. Metabolism. 1990;39:584–587
  7. Colletti RB, Copeland KC, Devlin JT, et al.  Effect of obesity on plasma insulin-like growth factor-I in cancer patients. Int J Obes. 1991;15:523–527
  8. Minuto F, Barreca A, Del Monte P, et al.  Spontaneous growth hormone and somatomedin-C/insulin-like growth factor-I secretion in obese subjects during puberty. J Endocrinol Invest. 1988;11:489–495
  9. Gama R, Teale JD, Marks V. The effect of synthetic very low calorie diets on the GH-IGF-1 axis in obese subjects. Clin Chim Acta. 1990;188:31–38
  10. Slowinska Srzednicka J, Zgliczynski W, Makowska A, et al.  An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome due to coexistent obesity. J Clin Endocrinol Metab. 1992;74:1432–1435
  11. Conover CA, Lee PD, Kanaley JA, et al.  Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab. 1992;74:1355–1360
  12. Cordido F, Casanueva FF, Vidal JI, et al.  Study of insulinlike growth factor I in human obesity. Horm Res. 1991;36:187–191
  13. Loche S, Cappa M, Borrelli P, et al.  Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: Evidence for somatomedin-C mediated inhibition. Clin Endocrinol (Oxf). 1987;27:145–153
  14. Van Vliet G, Bosson D, Rummens E, et al.  Evidence against growth hormone-releasing factor deficiency in children with idiopathic obesity. Acta Endocrinol. 1986;279:403–410 [Suppl] (Copenh)
  15. Caufriez A, Golstein J, Lebrun P, et al.  Relations between immunoreactive somatomedin C, insulin and T3 patterns during fasting in obese subjects. Clin Endocrinol (Oxf). 1984;20:65–70
  16. Rosskamp R, Becker M, Soetadji S. Circulating somatomedin-C levels and the effect of growth hormone-releasing factor on plasma levels of growth hormone and somatostatin-like immunoreactivity in obese children. Eur J Pediatr. 1987;146:48–50
  17. Phillips LS, Unterman TG. Somatomedin activity in disorders of nutrition and metabolism. Clin Endocrinol Metab. 1984;13:145–189
  18. Vasileva IA, Ostroumova MN, Dilman VM. Interrelation between lipidemia and somatomedin activity in cancer and age-associated pathology. Neoplasma. 1982;29:469–475
  19. Grzywa M. Serum somatomedin activity and growth hormone level in obese men: Dependence on degree of obesity and hyperlipidemia. Exp Clin Endocrinol. 1986;88:325–333
  20. Hagenas L. On growth hormone and adiposity in children. Int Growth Monitor. 1992;2:37–41
  21. DeFronzo RA, Ferrannini E. Insulin resistance. In: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. ed 2. Diabetes Care. 14:1991;p. 173–194
  22. Froesch ER, Guler HP, Schmid C, et al.  Therapeutic potential of insulin-like growth factor I. Trends Endocrinol Metab. 1990;1:254–260
  23. Suikkari AM, Koivisto VA, Koistinen R, et al.  Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J Clin Endocrinol Metab. 1989;68:135–140
  24. Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. In: ed 2. Proc Soc Exp Biol Med. 204:1993;p. 4–29
  25. Frystyk J, Skjærbæk C, Dinesen B, et al.  Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 1994;348:185–191
  26. Andersen L, Dinesen B, Jørgensen PN, et al.  Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993;39:578–582
  27. Frystyk J, Dinesen B, Ørskov H: Non-competitive time-resolved immunofluorometric assay for determination of human insulin-like growth factor I and II. Growth Regul (in press)
  28. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: A comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab. 1980;51:781–788
  29. Bang P, Stangenberg M, Westgren M, et al.  Decreased ternary complex formation and predominance of a 29 kDa IGFBP-3 fragment in human fetal serum. Growth Regul. 1994;4:68–76
  30. Daughaday WH, Kapadia M, Mariz I. Serum somatomedin binding proteins: Physiologic significance and interference in radioligand assay. J Lab Clin Med. 1987;109:355–363
  31. Hartman ML, Clayton PE, Johnson ML, et al.  A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest. 1993;91:2453–2462
  32. Lieberman SA, Bukar J, Chen SA, et al.  Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. J Clin Endocrinol Metab. 1992;75:30–36
  33. Zenobi PD, Graf S, Ursprung H, et al.  Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest. 1992;89:1908–1913
  34. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 1987;317:137–140
  35. Hizuka N, Takano K, Asakawa K, et al.  Measurement of free form of insulin-like growth factor I in human plasma. Growth Regul. 1991;1:51–55
  36. Boulware SD, Tamborlane WV, Matthews LS, et al.  Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol. 1992;262:E130–E133
  37. Guler HP, Eckardt KU, Zapf J, et al.  Insulin-like growth factor I increase glomerular filtration rate and renal plasma flow in man. Acta Endocrinol (Copenh). 1989;121:101–106
  38. Takada M, Nakanome H, Kishida M, et al.  Measurement of free insulin-like growth factor-I using immunoradiometric assay. J Immunoassay. 1994;15:263–276
  39. Baxter RC, Cowell CT. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab. 1987;65:432–440
  40. Baxter RC. Insulin-like growth factor (IGF) binding proteins: The role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand. 1991;372:107–114 [Suppl]
  41. Hall K, Brismar K, Grissom F, et al.  IGFBP-1. In: Production and control mechanisms. ed 2. Acta Endocrinol. 124:1991;p. 48–54 [Suppl] (Copenh)
  42. Brismar K, Fernqvist-Forbes E, Wahren J, et al.  Effect of insulin on the hepatic production of insulin-like growth factor binding protein-1 (IGFBP-1), IGFBP-3 and IGF-1 in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994;79:872–878
  43. Bar RS, Boes M, Clemmons DR, et al.  Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. Endocrinology. 1990;127:497–499
  44. Bang P, Brismar K, Rosenfeld RG, et al.  Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with noninsulin-dependent diabetes mellitus versus healthy nonobese and obese subjects. J Clin Endocrinol Metab. 1994;78:960–967
  45. Brismar K, Gutniak M, Povoa G, et al.  Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. J Endocrinol Invest. 1988;11:599–602
  46. Crosby SR, Tsigos C, Anderton CD, et al.  Elevated plasma insulin-like growth factor binding protein-1 levels in type 1 (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia. 1992;35:868–872
  47. Weaver JU, Holly JM, Kopelman PG, et al.  Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity. Clin Endocrinol (Oxf). 1990;33:415–422
  48. Kerr D, Tamborlane WV, Rife F, et al.  Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. In: A comparison with insulin. ed 2. J Clin Invest. 91:1993;p. 141–147
  49. Guler HP, Schmid C, Zapf J, et al.  Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. In: ed 2. Proc Natl Acad Sci USA. 86:1989;p. 2868–2872
  50. Bermann M, Jaffe CA, Tsai W, et al.  Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. In: Involvement of hypothalamic somatostatin. ed 2. J Clin Invest. 94:1994;p. 138–145
  51. Humbel RE. Insulin-like growth factors I and II. Eur J Biochem. 1990;190:445–462
  52. Costin G, Kogut MD, Phillips LS, et al.  Craniopharyngioma: The role of insulin in promoting postoperative growth. J Clin Endocrinol Metab. 1976;42:370–379
  53. Hochberg Z, Hertz P, Colin V, et al.  The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism. 1992;41:106–112

☆ Supported by grants from the Danish Medical Research Council, Institute of Experimental Clinical Research, University of Aarhus, the Danish Diabetes Association, the Novo Foundation, the NovoCare® Research Foundation, and the Aage Louis-Hansen Memorial Foundation.

PII: 0026-0495(95)90219-8

Metabolism - Clinical and Experimental
Volume 44 , Pages 37-44 , October 1995

Article Tools